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ORIGINAL ARTICLE

Langerhans Cell Histiocytosis Associated With Renal
Cell Carcinoma Is a Neoplastic Process
Clinicopathologic and Molecular Study of 7 Cases
Abbas Agaimy, MD,* Michael Bonert, MD,†‡ Asghar Naqvi, MD,‡ Chunjie Wang, MD,§
Kiril Trpkov, MD,∥ Peer Dettmar, MD,¶ Hanns-Olof Wintzer, MD,# Robert Stoehr, PhD,*
Ondřej Hes, MD,** Sean R. Williamson, MD,††‡‡ Ian W. Gibson, MD,§§
and Arndt Hartmann, MD*

Abstract: Langerhans cell histiocytosis (LCH) is a rare histiocytic
disorder composed of Langerhans cells admixed with reactive
mononuclear and granulocytic cells, associated with prominent
eosinophils. LCH is considered a neoplasm, driven in most cases
by oncogenic RAS/RAF/MEK/ERK pathway mutations. The disease predominantly affects children. Urinary system involvement
has rarely been reported in a multisystem disease setting. We describe 7 patients who presented with LCH occurring within
(6 cases) or after (1 case) a resected clear cell (n = 6) or clear cell
papillary (n = 1) renal cell carcinoma (RCC), identiﬁed prospectively in our routine and consultation ﬁles (2012 to 2019). The
patients included 5 women and 2 men, with a median age of
54 years (range, 39 to 73 y), none with a history of LCH or LCH
manifestations before the time of RCC diagnosis. The median size
of the RCC was 3.5 cm (range, 1.8 to 8.3 cm). Treatment included
partial (5 cases), or radical (2 cases) nephrectomy. All RCCs on
gross examination showed at least focal cystic changes and were
low grade (World Health Organization [WHO]/International Society of Urologic Pathologists [ISUP] grade 1 to 2). The LCH foci
were detected as incidental histological ﬁnding within the resected
RCC in all six cases and they were limited to few high-power ﬁelds
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(< 2 mm2) in 5 of 6 cases, but in the sixth case, they occupied
almost the entire clear cell papillary RCC (2 cm nodule). No LCH
manifestations were detected in the normal kidney or in perinephric fat. The seventh patient developed LCH within inguinal
deep soft tissue followed by systemic manifestations 6 years after
clear cell RCC. Langerhans cell immunophenotype was supported
by the reactivity for S-100, CD1a, and langerin and by the negative
pankeratin. Successful pyrosequencing of microdissected LCH
DNA revealed the V600E BRAF mutation in all 6 cases of LCH
within RCC. To our knowledge, only 3 similar cases were published since 1980; the only case tested for BRAF mutation showed
wild-type BRAF. This is the ﬁrst study analyzing the morphologic
and genetic features of a cohort of LCH associated with RCC. In
our experience, these cases may be underrecognized in practice, or
may erroneously be diagnosed as RCC dedifferentiation or highgrade sarcomatoid transformation. Finally, the detection of BRAF
mutation further conﬁrms that LCH in this setting is indeed a
neoplasm, rather than a reactive lesion.
Key Words: renal cell carcinoma, RCC, Langerhans cell histiocytosis, kidney, concurrent, BRAF V600E
(Am J Surg Pathol 2020;00:000–000)

L

angerhans cell histiocytosis (LCH) is an uncommon
proliferative histiocytic disorder composed of histologically bland Langerhans cells admixed with reactive mononuclear and granulocytic cells, often accompanied by
prominent eosinophils.1 Since its description > 1 century ago,
much controversy has accompanied the etiology, pathogenesis, terminology, classiﬁcation, and the treatment of
LCH. Currently, it has been widely accepted that LCH
represents a neoplastic disease of the Langerhans cells, driven
in most cases by oncogenic mutations in the RAS/RAF/
MEK/ERK pathway.1–5 Clinically, LCH may present as
unifocal (eosinophilic granuloma), multifocal unisystemic
(Hand-Schüller-Christian), or multifocal and multisystemic
(Letterer-Siwe) disease, with variable clinical manifestations
depending on the anatomic sites involved.1,2 The neoplastic
hallmark cell of LCH, “the Langerhans cell,” is characterized
by its histopathologic features, supplemented by the immunoexpression for CD1a, langerin (CD207), and S-100
www.ajsp.com
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TABLE 1. Clinicopathologic and Molecular Features of LCH Associated With RCC Including Previously (n = 3) and Currently (n = 7)
Reported Cases
Case
No. References Age/Sex
1

Mettler
et al8
Pimentel
et al9

2

No.
RCC

46/male

1

60/female

1

Size of RCC/
Site Within
Kidney

Treatment

1.5 cm/lower
pole right
3.1 cm/lower
pole

Enucleation

Left partial
NE
Left partial
NE

ccRCC with
cystic change

Left radical
NE

ccRCC with
cystic change

Right partial
NE

62/male

1

1.6 cm/mid-pole

4

Kwon
et al10
This study

39/male

1

4 cm/upper pole

5

This study

73/female

1

8.3 cm/uppermid-pole

6

This study

54/female

1

1.8 cm/interpolar Left partial
region
NE

7

This study

54/male

8

This study

45/male

1+5 mm
papillary
adenoma
4

9

This study

10

This study

3

Histology
of RCC
ccRCC (ccPRCC
possible)
ccRCC
ccRCC

Relationship
of LCH to Molecular
RCC
Findings
Within the
RCC
Multifocal
within
RCC
Within the
RCC
Within the
RCC

ND
ND
BRAF
wild-type
BRAF
V600E

Within RCC

BRAF
V600E

ccRCC mostly
Within RCC
solid, some cystic
component
ccPRCC with
Occupying
cystic change
most of
RCC
ccRCC with
Within RCC
cystic change

BRAF
V600E

2.5 cm/NS

Left partial
NE

0.4-3.5 cm

Left partial
NE

53/female 1+separate
“atypical
cyst”

1.8 cm

Right partial
NE

ccRCC

Within RCC

BRAF
V600E

58/female

6 cm/upper pole

Left radical
NE

ccRCC with
cystic change

LCH
presented
as inguinal
mass 6 y
after RCC

Failed

1

BRAF
V600E
BRAF
V600E

Follow-up
Systemic LCH since
age 12
No evidence of
systemic LCH
No evidence of
systemic LCH
No evidence of
systemic LCH,
ANED (7 mo)
Innumerable tiny
nodules in lung
bases unchanged,
ANED (17 mo)
No evidence of
systemic LCH,
ANED (42 mo)
No evidence of
systemic LCH,
lost to follow-up
No evidence of
systemic LCH,
ANED (60 mo)
No known systemic
LCH but no
additional
evaluation is done,
ANED (6 mo)
Multiple recurrences
of LCH (gluteal,
pleura,
mediastinal) over
next 9 y

ANED indicates alive with no evidence of disease; mo, months; ND, not done; NE, nephrectomy; NS, not speciﬁed.

protein, and/or demonstration of Birbeck granules by electron microscopy.1 Both the localized and systemic diseases
predominantly affect children, whereas young adults are less
frequently, and older people are only rarely affected.1,2 The
treatment and the prognosis depend on the extent and dynamic of the disease.2–4
Systemic LCH may involve visceral organs, such as
lung and liver, in addition to bone, bone marrow, lymph
nodes, and spleen.1,2 Urogenital involvement by LCH is
very rare and has been typically documented in patients
with the multisystemic disease.2,6,7
In this study, we describe a cohort of 7 LCH lesions
associated with renal cell carcinoma (RCC), encountered in
our routine and consultation practice, and all but 1 case were
identiﬁed incidentally within resected RCCs. This ﬁnding was
a source of confusion and created diagnostic uncertainty that
led to consider in the differential diagnosis, either RCC dedifferentiation or high-grade sarcomatoid transformation.
Review of the literature uncovered only 3 similar cases, published as individual case reports since 1980 (Table 1, cases 1 to
3),8–10 with only 1 reported in a pathology journal.10 We,
therefore, propose that this phenomenon is possibly more

2 | www.ajsp.com

frequent than the literature implies and potentially signiﬁcantly
underrecognized by pathologists. We hope that our report will
draw the attention of general surgical and urological
pathologists to this potentially misleading ﬁnding.

MATERIALS AND METHODS
The cases have been identiﬁed by the authors during the
period from 2012 to 2019. Only case 7 predated this period and
was identiﬁed by the ﬁrst author. No retrospective search for
additional cases in our archives was performed. The LCH was
detected as incidental histologic ﬁnding within the resected
RCC in 6 cases and developed years after nephrectomy for
clear cell renal cell carcinoma (ccRCC) in 1 patient. Diagnosis
and subtyping of the RCC have been reviewed according to the
current World Health Organization (WHO) classiﬁcation.11
LCH was diagnosed in accordance with established histopathologic and immunophenotypic criteria.1
All samples have been formalin-ﬁxed and processed
routinely for histopathologic evaluation. Gross reports were
evaluated for size, location, and laterality of the tumor and
for the presence of cystic features on gross examination.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
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A cystic component was also recorded if present on microscopic evaluation. Immunohistochemistry (IHC) was performed on 3 µm sections cut from parafﬁn blocks using a
fully automated system (“Benchmark XT System,” Ventana
Medical Systems Inc., Tucson, AZ) and the following antibodies: S-100 protein (polyclonal, 1:2500; Dako), CD1a
(clone EP81, 1:100; Quartett/Epitomics), cyclin D1 (clone
SP4, 1:50; Zytomed), langerin/CD207 (clone 12D6, 1:100;
Novocastra), pankeratin (clone AE1/AE3, 1:40; Zytomed),
CK7 (OV-TL, 1:1000; Biogenex), and PAX8 (rabbit polyclonal, 1:50; Cell Marque). The BRAF IHC was performed
using the VE1–mutation-speciﬁc mouse monoclonal antibody (clone ab228461, 1:100; Abcam). Only cytoplasmic
staining was considered speciﬁc.

BRAF Mutation Testing
Microdissection and DNA Isolation
For molecular analysis, 5 μm sections were cut from
formalin-ﬁxed parafﬁn-embedded tissue specimens, deparafﬁnized, and rehydrated. The LCH foci were microdissected manually with a sterile scalpel. DNA isolation
was performed using the Maxwell 16 system and the
Maxwell 16 LEV Blood DNA Kit (Promega, Madison,
WI) according to the manufacturer’s instruction. Analysis
of BRAF V600 mutation hotspot was performed at the
institutional-accredited molecular diagnostics laboratory
using standardized and validated in-house protocols
(including DNA from the colon carcinoma cell line
HCT116 as a BRAF p.V600 wild-type control, DNA
from the colon carcinoma cell line HT 29 as a BRAF p.
V600E positive control as well as a reaction mix without
DNA as a negative control) and a PyroMark Q24 system
(QIAGEN, Hilden, Germany) according to manufacturer’s instructions.

RESULTS
LCH Detected Within Resected RCC (n = 6)
Clinical Features
The clinicopathologic features are summarized in
Table 1 (cases 4 to 9). Six patients who had LCH within a
resected RCC were identiﬁed. The 6 patients include 4
women and 2 men aged 39 to 73 years (median, 54 y). None
had a prior history of LCH, and diagnosis of LCH was ﬁrst
made after the evaluation of the nephrectomy specimens,
because the LCH lesions were conﬁned to the RCC tissue,
and represented incidental histologic ﬁndings in all cases.
Additional clinical investigations showed no evidence of
systemic disease in any of the patients. Of note, 1 patient had
numerous basal lung nodules consistent with a reactive
process, but biopsies were not obtained and the possibility of
pulmonary LCH cannot be ruled out with certainty. All
tumors but one were located in the left kidney. The treatment
included partial (5/6) and radical (1/6) nephrectomy. Followup was available for 5 patients and ranged 6 to 60 months
(median, 17 mo). All patients remained RCC free at the last
follow-up, and none had systemic LCH manifestation,
neither in the kidney nor in other organs.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

LCH Within RCC

Pathologic Findings
Five patients had solitary RCC ranging in size from
1.8 to 8.3 cm (median, 3 cm). The sixth patient had a
multifocal (n = 4) RCC ranging in size from 0.4 to 3.5 cm.
The LCH lesion in this patient was located within the
largest RCC nodule. Grossly, the RCCs were wellcircumscribed with variegated, variably cystic and solid,
yellow-tan cut-surface, and focal hemorrhagic areas.
Histologic examination was consistent with conventional
ccRCC in 5 patients and with clear cell papillary renal cell
carcinoma (ccPRCC) in 1 case. Notably, all RCCs showed
at least focal cystic changes that were typically recognizable grossly. All RCCs had low-grade nuclear features
according to the WHO/International Society of Urologic
Pathologists (ISUP) grading (grade 1 to 2); none showed
coagulative necrosis, rhabdoid, or sarcomatoid features.
All RCCs were conﬁned to the kidney, without evidence of
vascular invasion, perinephric fat involvement, or other
aggressive features.
Within the RCC itself, the LCH foci presented either as
basophilic staining cellular foci, sharply demarcated from the
surrounding RCC tissue or as multifocal hemorrhagic foci
(Figs. 1A–D). At higher magniﬁcation, atypical histiocytic
inﬁltrates showing cells with convoluted nuclear contours and
nuclear grooves were appreciated (Fig. 1E). The cells had
moderate pale to eosinophilic cytoplasm, compatible with the
histologic features of Langerhans cells. Numerous eosinophils
were also present in the background (Fig. 1E). In other areas
showing paucity of eosinophils and predominance of
Langerhans cells, the abrupt transition from the RCC to
the basophilic staining LCH tissue mimicked high-grade
transformation (Fig. 1F). The LCH foci were in most cases
limited to only a few high-power microscopic ﬁelds.
However, in 1 case (ccPRCC), the LCH areas occupied
almost the whole RCC nodule, with only minimal ccPRCC.
The ccPRCC in this case was hard to identify on hematoxylin
and eosin staining in most of the slides (Figs. 2A–F), but was
readily highlighted by IHC stains with CK7, PAX8, and
CA-9. The LCH showed variable cellularity and eosinophils
(Figs. 2B, C). Immunohistochemically, the LCH cells were
uniformly positive for langerin (Fig. 3A), CD1a (Figs. 3B, C),
S-100 (Fig. 3D), and cyclin D1 (Fig. 3E) and were negative
for pancytokeratin AE1/AE3 and PAX8. The ccPRCC
strongly expressed CK7 (Fig. 3F). The cystic spaces were
predominantly lined by LCH cells (Figs. 3A, B) and focally
by RCC cells (Fig. 3C).

Molecular Findings
The BRAF V600 analysis gave interpretable results
in all 6 cases, and positive and negative controls showed
the expected results underlining the validity of the analyses. The analysis revealed the c.1799T > A transversion in
all cases, indicating the classic BRAF V600E mutation.
IHC with the VE1–mutation-speciﬁc antibody was successful in 3 cases (cases 6, 7, and 9); all showed homogeneous cytoplasmic reactivity limited to the neoplastic
LCH cells (Fig. 4). Surrounding RCC cells are negative.
www.ajsp.com
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FIGURE 1. Whole mount sections showing distribution and extent of LCH within ccRCC (A, hematoxylin and eosin; B, an overview
of langerin immunostaining highlighting the LCH). C, ccRCC with solid and cystic areas associated with multiple hemorrhagic LCH
foci. D, Eosinophil-rich LCH infiltrate associated with fibrosis might be mistaken for regressive changes. E, Higher magnification of
the LCH shows prominent eosinophils and characteristic cytology of LCH cells. F, This eosinophil-poor LCH focus closely mimics the
high-grade transformation of the RCC. Images (A) and (B) from case 8; C–F from case 6 (for case numbers see Table 1). Copyright
© 2018 Michael Bonert, MD, FRCPC. You are free to share and adapt these image as per the CC BY-SA 4.0 (https://
creativecommons.org/licenses/by-sa/4.0/legalcode; https://commons.wikimedia.org/wiki/File:Langerhans_cell_histocytosis_within_
RCC_- -_extremely_low_mag.jpg; https://commons.wikimedia.org/wiki/File:Langerhans_cell_histocytosis_within_RCC_- -_low_mag.
jpg; https://commons.wikimedia.org/wiki/File:Langerhans_cell_histocytosis_within_RCC_- -_very_high_mag.jpg).

LCH Following RCC (n = 1)
This concerns a 58-year-old female patient who had a
history of left radical nephrectomy performed for a 6 cm
ccRCC originating in the upper pole of the left kidney. She
presented 6 years later with a 13-cm inguinal deep soft
tissue mass that was resected (Fig. 5A). Histology showed
mass-forming LCH with the involvement of adjacent
lymph nodes as well (Fig. 5B). Features of frankly
malignant Langerhans cell sarcoma were absent. Over the
next 9 years, the patient presented with multiple recurrences

4 | www.ajsp.com

of the LCH with progressive multifocal gluteal, pleura, and
mediastinal LCH manifestations. Attempted molecular
testing of this case was unsuccessful owing to poor DNA
quality. The ccRCC slides from 1998 were retrieved and
reviewed. Histology showed conventional ccRCC (ISUP/
WHO grade 2) with variable cystic foci. There was no
angioinvasion, perirenal involvement, or other aggressive
features. No LCH was detected within the RCC. There
was, however, only 4 parafﬁn blocks available from the 6
cm large RCC, and extensive sampling was not done.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 2. A, Overview of ccPRCC with prominent cystic areas and extensive replacement by LCH (inset: an overview of langerin
immunostaining shows almost complete replacement of the tumor by LCH). B and C, Cellular areas of LCH mimic sarcomatoid
transformation (confluent eosinophils in B simulate necrosis). D, Typical epithelial nests of the ccPRCC with antipolar small uniform
nuclei are seen (left) juxtaposed to hemorrhagic LCH (right). E, Higher magnification of the RCC component in (D). F, In most of
the slides, the ccPRCC was represented by minute foci amid LCH infiltrate. Images from case 7.

DISCUSSION
The pathogenesis of LCH has puzzled scientists and
clinicians for decades since the entity was recognized last
century. The dual theory “reactive-inﬂammatory versus
neoplastic” has evolved into the favor of the neoplastic
hypothesis based on demonstration of clonality of the
LCH cells and a high incidence of somatic activating
BRAF V600E point mutation.3–5 The frequency of BRAF
V600E mutation in LCH seems to vary based on the
method used for analysis and was reported to be as high as
70% in some series.1,3–5 Furthermore, MAP2K1 mutations
were detected as well, mainly in BRAF wild-type, and also
in a small subset of BRAF mutant lesions.3–5 Besides
BRAF, some lesions harbored additional deleterious
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

TP53 mutations.5 Likewise, expression of cyclin D1 was
observed in neoplastic LCH but not in clearly reactive
lesions.12 All these observations are consistent with a true
neoplastic lesion and argue against the old reactiveinﬂammatory theory.
LCH has been reported to be associated with a variety of hematological and solid malignancies, of which
lymphoma, leukemia, and lung carcinoma are the most
common.13–15 LCH may occur before, after, or be concomitant with a separate malignancy. Among solid tumors
associated with LCH, carcinoma of the lung and the
thyroid gland are the major types encountered, followed
by rare cases of breast cancer, liver cancer, sarcomas, and
central nervous system tumors.13–15 Diagnosis of the
www.ajsp.com
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FIGURE 3. IHC revealed diffuse expression of langerin (A), CD1a (B, C), S-100 (D), and cyclin D1 (E). Note the lining of cystic
spaces by LCH cells in (A) and (B) and by alternating CD1a-positive LCH cells (lower part, red arrows) and CD1a-negative RCC cells
(upper part, black arrows). F, The ccPRCC case (left part of the image) shows homogeneous CK7 reactivity, while the LCH on right
is negative. Images A, B, D, E, and F from case 7. Image C from case 5.

carcinoma and the LCH was concurrent in most lung
carcinoma and thyroid carcinoma cases.13 Notably, the
LCH was conﬁned to the lung in cases of lung carcinoma.
Moreover, the LCH lesions were intimately associated
with the carcinoma or lymphoma tissue in most cases, so
that both entities usually were diagnosed concurrently as
in our cases. Hammar et al16 detected Langerhans cells in
close association with the neoplastic epithelial cells in 7 of
37 bronchoalveolar lung carcinomas. These observations,
which are very similar to our current study, suggested that
the LCH lesions in these cases represent a dendritic cell
reaction in response to a stimulus related to the associated
solid cancer (lung carcinoma or lymphoma).13 On the
contrary, most solid cancers preceded by LCH developed
at the site of irradiation for the LCH, indicating that the

6 | www.ajsp.com

association between solid cancer and the LCH is coincidental and is likely a consequence of irradiation.13
The reported coexistence of LCH and RCC, as in our
current series, is extremely rare. The frequency of LCH detected within a resected RCC is unknown. In our institutional
ﬁles, RCCs containing foci of LCH represent 0.1% to 0.3% of
all RCC cases diagnosed during the study period. There are
only 3 previous reports in the English literature from 1980,8
2011,9 and 2018,10 with the more recent report published in a
surgical pathology journal. The ﬁrst previously reported case
was that of a 46-year-old man with a history of eosinophilic
granuloma of the left mastoid at age 12, treated with curettage and radiation. Thirty-four years after the initial presentation, the patient was found to have an eosinophilic
granuloma of the left mid-humerus, in addition to a 1 cm
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 4. A, IHC using the VE1–mutation-specific antibody highlights specifically the neoplastic LCH cells including those LCH
cells lining the cysts (note absence of staining in lymphoid cells in B). Images from case 7.

RCC in close association with LCH in the right kidney.8 The
second and third previously reported cases were of a 60-yearold woman and a 60-year-old man who were incidentally
found to have a renal mass, which was histologically conﬁrmed to be RCC, harboring microscopic foci of LCH.9,10 In
all 3 cases, the LCH was intimately associated with the RCC
component. Six of the 7 cases included in the current study
demonstrated this same feature.
The fundamental pathogenesis of the association of
LCH with other tumors is largely unknown. Most authors
speculate that the tumor microenvironment may play a
critical role in recruiting Langerhans cells to migrate and
proliferate in organs/tissues where tumor cells reside, as they
can produce a wide variety of cytokine/chemokine-like
factors with mitogenic and chemotactic functions.8,13 In our
cases, the ﬁndings of LCH in close association with the
RCC, and without other manifestations of systemic LCH
disease, imply that a focal LCH lesion occurred as a secondary reaction to the primary tumor, the RCC.13 The
pathogenesis of this peculiar phenomenon is unclear.

Previous studies on LCH associated with diverse malignant
neoplasms suggested both a reactive etiology (especially for
those lesions intimately associated with a synchronous malignancy such as malignant lymphoma and lung adenocarcinoma),13 as well as therapy-related pathogenesis
(for those cases with a remote history of a previous malignancy such as leukemia and cases where solid cancer developed in the irradiation ﬁeld for the LCH).13 To our
knowledge, only one of the previously reported LCH cases
within RCC was investigated for BRAF mutations and
showed negative results.10 Accordingly, reactive pathogenesis remained likely.
We, therefore, examined all cases for BRAF mutations
trying to address the question of reactive LCH lesions versus
genuine neoplastic LCH. Indeed, all of 6 analyzable cases
revealed the same V600E BRAF mutation, thus conﬁrming
that these represented true neoplastic LCH and excluding an
LCH-like reactive-inﬂammatory lesion in response to the
RCC. However, the answer to the question of why the LCH
did develop within the RCC proper itself remains elusive.

FIGURE 5. This 13-cm deep soft tissue mass (A) excised from the inguinal area of a 58-year-old woman with a history of ccRCC
proved to be a huge mass-forming LCH (B). A review of the slides of the previous ccRCC showed no LCH. Images from case 10.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
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Likewise, the observation that all cases and likely all previously reported cases (except for 1 ccPRCC) are low-grade
ccRCC with variable cystic changes remains unclear. The
prevalence of ccRCC in this unique small cohort is possibly
not by chance; this suggests the subtype may play a role in
the coexistence of these 2 distinct entities, but the low
number of cases does not allow for statistical analysis. All 6
cases described herein did not show any progression or wide
dissemination of the LCH after resection of the RCC. This
supports an indolent nature of the LCH and that resection
of the “host” RCC was a sufﬁcient treatment for both lesions, although close clinical follow-up is warranted. The
seventh additional case we describe herein showed progressive systemic LCH developing years after ccRCC in a
58-year-old female patient. Although we were not able to
clearly identify LCH lesions within the ccRCC in this patient, it cannot be completely ruled out that this patient´s
ccRCC did harbor foci of LCH that were possibly not
sampled, given that only limited number of slides were
provided from her large RCC.
From a diagnostic viewpoint, the most relevant
message would be to distinguish LCH within RCC from
focal high-grade sarcomatoid transformation or dedifferentiation of the RCC. Indeed, one of the cases was sent to
us with a diagnosis of dedifferentiated RCC. Therefore, a
careful assessment of the morphology is required for distinguishing LCH cells from the RCC cells. However, a
subset of RCC of different types (chromophobe carcinomas in particular) may rarely display prominent nuclear
grooves, resulting in coffee bean-shaped nuclei that may
resemble those of LCH. However, these cells are usually
present throughout the neoplasm and are not associated
with an eosinophil-rich inﬂammatory background as seen
in LCH lesions. IHC provides a reliable way to distinguish
LCH (positive for S-100, CD1a, and langerin) from
grooved RCC cells (positive for cytokeratins and PAX8).
Another possibility to be considered when encountering a
strange-looking cell population within an otherwise lowgrade RCC is “tumor-to-tumor metastasis.” Indeed, RCC
represents the most common recipient of metastases, the
donor neoplasm being lung carcinoma in the majority of
cases.17 Up to 15% of cases of RCC with a concurrent
second malignancy harbored metastatic foci.17 Last but
not least, the detection of a BRAF mutation in such RCC
specimens with foci of LCH should not be mistaken for
BRAF-mutated RCC with the consequence of false therapeutic recommendations. Although being universally
present in metanephric adenomas,18 BRAF mutations
seem to be very rare in ccRCC.19 The mutation-speciﬁc
anti-BRAF VE1 antibody conﬁrmed the presence of the
mutated BRAF protein in the LCH cells and its absence in
the surrounding RCC cells.
In summary, we describe 6 cases of low-grade RCC
harboring foci of LCH located within, and in 1 case replacing the RCC to a variable extent, and the seventh case
of progressive LCH developing years after ccRCC. LCH
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within resected RCC may be mistaken for high-grade
sarcomatoid transformation if not correctly identiﬁed. The
presence of BRAF mutations in all intra-RCC LCH lesions conﬁrmed a true neoplasm (tumor-in-tumor development) and argued against a reactive process. The
pathogenesis of this rare ﬁnding remains to be explored in
future studies.
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